Opinion Don't Sit Shiva for Teva Yet, It's Going to Rebound

The beleaguered Israeli drugs company is well-positioned for an inevitable turnaround in the generics market, if its new CEO Kare Schultz can get its finances in order,

comments Print
It’s inevitable that troubled drug companies find themselves compared to sickly patients. That was Teva Pharmaceuticals’ fate last week when it turned in another quarter of dismal earnings, yet again. “Ouch!...